[HTML][HTML] Impact of additional chromosomal aberrations and BCR-ABL kinase domain mutations on the response to nilotinib in Philadelphia chromosome-positive …
TD Kim, S Türkmen, M Schwarz, G Koca, H Nogai… - …, 2010 - ncbi.nlm.nih.gov
TD Kim, S Türkmen, M Schwarz, G Koca, H Nogai, C Bommer, B Dörken, P Daniel…
Haematologica, 2010•ncbi.nlm.nih.govBackground Additional chromosomal aberrations in Philadelphia chromosome-positive
chronic myeloid leukemia are non-random and strongly associated with disease
progression, but their prognostic impact and effect on treatment response is not clear. Point
mutations in the BCR-ABL kinase domain are probably the most common mechanisms of
imatinib resistance.
chronic myeloid leukemia are non-random and strongly associated with disease
progression, but their prognostic impact and effect on treatment response is not clear. Point
mutations in the BCR-ABL kinase domain are probably the most common mechanisms of
imatinib resistance.
Abstract
Background
Additional chromosomal aberrations in Philadelphia chromosome-positive chronic myeloid leukemia are non-random and strongly associated with disease progression, but their prognostic impact and effect on treatment response is not clear. Point mutations in the BCR-ABL kinase domain are probably the most common mechanisms of imatinib resistance.
ncbi.nlm.nih.gov